+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study



Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study



Annals of Saudi Medicine 36(3): 216-222



Knowing risk factors for colistin resistance is important since colistin is the only remaining choice for the treatment of infections caused by multi-drug resistant microorganisms. Evaluate risk factors associated with infection by colistin-resistant microorganisms. Retrospective study. Tertiary healthcare centers. An e-mail including the title and purpose of the study was sent to 1500 infec.tious disease specialists via a scientific and social web portal named "infeksiyon dunyasi (infection world)". Demographic and clinical data was requested from respondents. Colistin-resistance. Eighteen infectious disease specialists from twelve tertiary care centers responded to the invitation data was collected on 165 patients, 56 cases (39.9%) and 109 (66.0%) age- and sex-matched controls. The colistin-resistant microorganisms isolated from cases were 29 Acinetobacter baumannii (51.8%), 18 Pseudomonas aeruginosa (32.1%) and 9 Klebsiella spp. Colistin, carbapenem, and quinolone use in the last three months were risk factors for colistin resistance in the univariate analysis. Previous quinolone use in the last three months (P=.003; RR:3.2; 95% Ci:1.5-6,7) and previous colistin use in the last three months (P=.001; RR: 3.6; 95% CI: 1.63-7.99) were significant risk factors in the multivariate analysis. Clinicians should limit the use of quinolones and remain aware of the possibility of resistance developing during colistin use. The lack of a heteroresistance analysis on the isolates. no data on use of a loading dose or the use of colistin in combination.

(PDF emailed within 1 workday: $29.90)

Accession: 058778649

Download citation: RISBibTeXText

PMID: 27236394


Related references

Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors. Infection 41(6): 1195-1198, 2014

Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Critical Care Medicine 36(3): 807-811, 2008

Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?. Diagnostic Microbiology and Infectious Disease 85(2): 233-238, 2017

Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea. Diagnostic Microbiology and Infectious Disease 78(4): 457-461, 2014

Case control study of risk factors rf for nosocomial infection with fluoroquinolone fq and aminoglycoside ag resistant gram negative bacteria. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 216, 1992

Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. European Journal of Clinical Pharmacology 69(7): 1429-1436, 2013

Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clinical Microbiology and Infection 17(11): E9-E11, 2012

Synergistic Activity of Colistin in Combination With Resveratrol Against Colistin-Resistant Gram-Negative Pathogens. Frontiers in Microbiology 9: 1808, 2018

Risk factors for multidrug-resistant Gram-negative infection in burn patients. Anz Journal of Surgery 88(5): 480-485, 2017

Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria. Journal of ChemoTherapy 26(4): 211-216, 2015

Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. International Journal of Antimicrobial Agents 35(3): 297-300, 2010

Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clinical Microbiology and Infection 12(5): 497-498, 2006

Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. Journal of Burn Care and Research 28(3): 421-426, 2007

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. Bmj Open 6(4): E009956, 2017

Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clinical Microbiology and Infection 12(12): 1227-1230, 2006